\
&
Contact us
This was 10 months ago
Locationonline
ProgrammesThis MSCA lunchtime conversation session will focus on digital democracy and digital skills that citizens need to critically navigate the online public sphere.
It will look into different aspects of democratic participation in the era of social media and online platforms exposed to fake news and dis/misinformation, and the role of artificial Intelligence in shaping the ways of consuming and creating content.
Like the first event, the second MSCA lunchtime conversation will bring together representatives of different Commission services and scientific leaders/coordinators of EU-funded projects to present their work on the topic and engage in an active discussion with each other and with the audience (individual researchers, project leaders, policy makers, practitioners, civil society representatives, interested citizens).
More information and the registration link is available in the announcement on the MSCA website.
Programme in brief
12:30 - 12:35 Event introduction
12:35 - 12:45 Policy context and project data by MSCA
12:45 - 13:45 Discussion panel
13:45 - 13:55 Policy reflections
13:55 - 14:00 Wrap up and announcement of next events
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.